The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice

PLoS One. 2017 Apr 14;12(4):e0175564. doi: 10.1371/journal.pone.0175564. eCollection 2017.

Abstract

Objective: We aimed to evaluate the correct assignment of HCV genotype/subtypes 1a and 1b by cobas® HCV genotyping (GT) assay (Roche Molecular Diagnostics) compared with nonstructural protein 5B (NS5B) sequencing.

Patients and methods: Clinical samples from 153 patients submitted for HCV genotyping were studied. After genotyping with the cobas® HCV GT, sequencing of a 387 bp fragment in the NS5B gene and phylogenetic analysis was employed to compare genotyping results. Major discrepancies were defined as differences in the assigned genotype by cobas® HCV GT and NS5B sequencing (including genotype 1 subtypes 1a and 1b misclassification).

Results: Overall agreement between the cobas® HCV GT and NS5B sequencing was 98%; all the 1a, 1b, 2, 3 and 4 genotypes identified by cobas® HCV GT were concordant with NS5B sequencing. Three samples tested "indetermined" by cobas® HCV GT assay and were genotyped as 1a, 3a, and 4d by NS5B sequencing.

Conclussion: These results indicate that the cobas® HCV GT assay correctly identifies HCV genotypes, and points out the importance of additional methods based on DNA sequencing for resolving indeterminate results.

Publication types

  • Comparative Study

MeSH terms

  • Genotype
  • Hepacivirus / genetics*
  • Hepacivirus / isolation & purification
  • Hepatitis C / diagnosis*
  • Hepatitis C / virology
  • Humans
  • Molecular Typing / methods*
  • Phylogeny
  • RNA, Viral / genetics
  • RNA, Viral / metabolism
  • Reagent Kits, Diagnostic
  • Real-Time Polymerase Chain Reaction
  • Sequence Analysis, RNA
  • Viral Nonstructural Proteins / classification
  • Viral Nonstructural Proteins / genetics

Substances

  • RNA, Viral
  • Reagent Kits, Diagnostic
  • Viral Nonstructural Proteins

Grants and funding

This work was supported in part by grants from Fondo de Investigación Sanitaria (www.isciii.es) (PI15/00713), Plan Nacional de I+D+I and Fondo Europeo de Desarrollo Regional-FEDER (www.red.es/redes/inicio) (RD12/0017/006), and Fundación Progreso y salud, Junta de Andalucía (www.fps2.junta-andalucia.es/fundacionprogresoysalud/es/home) (PI-0411-2014). Federico García has received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio Andaluz de Salud.